REV-500

N/A

Report date: 2025/01/26 17:49:18
NME

Base Information

Drug NameREV-500
Drug Alias Nameimmune checkpoint inhibitor (Revitope Oncology)REV-500
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRevitope Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesRevitope Oncology Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A